STOCK TITAN

[Form 4] Nuvation Bio Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider Purchase Alert: Colleen Sjogren, Chief Commercial Officer of Nuvation Bio (NUVB), has acquired 50,000 shares of Class A Common Stock on June 16, 2025, at a weighted average price of $1.807 per share, representing a total investment of approximately $90,350.

Following this transaction, Sjogren now beneficially owns 81,000 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed in multiple transactions with prices ranging from $1.795 to $1.82 per share.

This insider purchase by a senior executive could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with securities regulations, with the filing submitted through an attorney-in-fact on June 18, 2025.

Avviso di Acquisto da Insider: Colleen Sjogren, Chief Commercial Officer di Nuvation Bio (NUVB), ha acquistato 50.000 azioni di Classe A Common Stock il 16 giugno 2025, ad un prezzo medio ponderato di $1,807 per azione, per un investimento totale di circa 90.350 dollari.

Dopo questa operazione, Sjogren detiene direttamente in modo beneficiario 81.000 azioni, incluse 3.000 azioni precedentemente acquisite tramite il Piano di Acquisto Azionario per Dipendenti 2021 della società, il 19 maggio 2025. L'acquisto è stato effettuato in più transazioni con prezzi compresi tra $1,795 e $1,82 per azione.

Questo acquisto da parte di un dirigente senior potrebbe indicare fiducia nelle prospettive future dell'azienda. L'operazione è stata comunicata tramite la presentazione del Modulo 4 ed eseguita nel rispetto delle normative sui titoli, con la documentazione depositata tramite un procuratore il 18 giugno 2025.

Alerta de Compra de Insider: Colleen Sjogren, Directora Comercial de Nuvation Bio (NUVB), adquirió 50,000 acciones de Clase A Common Stock el 16 de junio de 2025, a un precio promedio ponderado de $1.807 por acción, representando una inversión total aproximada de $90,350.

Tras esta transacción, Sjogren posee ahora beneficiosamente 81,000 acciones directamente, incluyendo 3,000 acciones adquiridas previamente a través del Plan de Compra de Acciones para Empleados 2021 de la compañía el 19 de mayo de 2025. La compra se realizó en múltiples transacciones con precios que oscilaron entre $1.795 y $1.82 por acción.

Esta compra por parte de un ejecutivo senior podría señalar confianza en las perspectivas futuras de la empresa. La transacción fue reportada mediante la presentación del Formulario 4 y ejecutada conforme a las regulaciones de valores, con la presentación realizada a través de un apoderado el 18 de junio de 2025.

내부자 매수 알림: Nuvation Bio(NUVB)의 최고상업책임자(Chief Commercial Officer)인 Colleen Sjogren이 2025년 6월 16일에 클래스 A 보통주 50,000주를 주당 가중평균 가격 $1.807에 매수하여 총 약 $90,350의 투자를 진행했습니다.

이번 거래 후 Sjogren은 회사의 2021년 직원 주식 매입 계획을 통해 2025년 5월 19일에 취득한 3,000주를 포함하여 직접적으로 81,000주를 보유하게 되었습니다. 매수는 주당 $1.795에서 $1.82 사이의 가격으로 여러 차례 나누어 이루어졌습니다.

이 고위 임원의 내부자 매수는 회사의 미래 전망에 대한 신뢰를 나타낼 수 있습니다. 해당 거래는 Form 4 신고를 통해 보고되었으며, 증권 규정을 준수하여 2025년 6월 18일 대리인을 통해 신고되었습니다.

Alerte d'Achat d'Initié : Colleen Sjogren, Directrice Commerciale de Nuvation Bio (NUVB), a acquis 50 000 actions de Classe A Common Stock le 16 juin 2025, à un prix moyen pondéré de 1,807 $ par action, représentant un investissement total d'environ 90 350 $.

Suite à cette transaction, Sjogren détient désormais directement 81 000 actions bénéficiaires, incluant 3 000 actions acquises précédemment via le Plan d'Achat d'Actions Employés 2021 de la société, le 19 mai 2025. L'achat a été réalisé en plusieurs transactions avec des prix variant entre 1,795 $ et 1,82 $ par action.

Cette acquisition par un cadre supérieur pourrait indiquer une confiance dans les perspectives futures de l'entreprise. La transaction a été déclarée via le dépôt du Formulaire 4 et exécutée conformément aux régulations sur les valeurs mobilières, le dépôt ayant été effectué par un mandataire le 18 juin 2025.

Insider-Kaufmeldung: Colleen Sjogren, Chief Commercial Officer von Nuvation Bio (NUVB), hat am 16. Juni 2025 50.000 Aktien der Klasse A Common Stock zu einem gewichteten Durchschnittspreis von 1,807 $ pro Aktie erworben, was einer Gesamtinvestition von etwa 90.350 $ entspricht.

Nach dieser Transaktion besitzt Sjogren nun direkt wirtschaftlich 81.000 Aktien, darunter 3.000 Aktien, die zuvor am 19. Mai 2025 über den Mitarbeiteraktienkaufplan 2021 des Unternehmens erworben wurden. Der Kauf erfolgte in mehreren Transaktionen zu Preisen zwischen 1,795 $ und 1,82 $ pro Aktie.

Dieser Insider-Kauf eines leitenden Angestellten könnte auf Vertrauen in die zukünftigen Aussichten des Unternehmens hinweisen. Die Transaktion wurde über eine Form 4-Meldung gemeldet und unter Einhaltung der Wertpapierbestimmungen ausgeführt, wobei die Meldung am 18. Juni 2025 durch einen Bevollmächtigten eingereicht wurde.

Positive
  • Chief Commercial Officer made significant open market purchase of 50,000 shares at $1.807 per share, totaling approximately $90,350, demonstrating insider confidence in company
Negative
  • None.

Avviso di Acquisto da Insider: Colleen Sjogren, Chief Commercial Officer di Nuvation Bio (NUVB), ha acquistato 50.000 azioni di Classe A Common Stock il 16 giugno 2025, ad un prezzo medio ponderato di $1,807 per azione, per un investimento totale di circa 90.350 dollari.

Dopo questa operazione, Sjogren detiene direttamente in modo beneficiario 81.000 azioni, incluse 3.000 azioni precedentemente acquisite tramite il Piano di Acquisto Azionario per Dipendenti 2021 della società, il 19 maggio 2025. L'acquisto è stato effettuato in più transazioni con prezzi compresi tra $1,795 e $1,82 per azione.

Questo acquisto da parte di un dirigente senior potrebbe indicare fiducia nelle prospettive future dell'azienda. L'operazione è stata comunicata tramite la presentazione del Modulo 4 ed eseguita nel rispetto delle normative sui titoli, con la documentazione depositata tramite un procuratore il 18 giugno 2025.

Alerta de Compra de Insider: Colleen Sjogren, Directora Comercial de Nuvation Bio (NUVB), adquirió 50,000 acciones de Clase A Common Stock el 16 de junio de 2025, a un precio promedio ponderado de $1.807 por acción, representando una inversión total aproximada de $90,350.

Tras esta transacción, Sjogren posee ahora beneficiosamente 81,000 acciones directamente, incluyendo 3,000 acciones adquiridas previamente a través del Plan de Compra de Acciones para Empleados 2021 de la compañía el 19 de mayo de 2025. La compra se realizó en múltiples transacciones con precios que oscilaron entre $1.795 y $1.82 por acción.

Esta compra por parte de un ejecutivo senior podría señalar confianza en las perspectivas futuras de la empresa. La transacción fue reportada mediante la presentación del Formulario 4 y ejecutada conforme a las regulaciones de valores, con la presentación realizada a través de un apoderado el 18 de junio de 2025.

내부자 매수 알림: Nuvation Bio(NUVB)의 최고상업책임자(Chief Commercial Officer)인 Colleen Sjogren이 2025년 6월 16일에 클래스 A 보통주 50,000주를 주당 가중평균 가격 $1.807에 매수하여 총 약 $90,350의 투자를 진행했습니다.

이번 거래 후 Sjogren은 회사의 2021년 직원 주식 매입 계획을 통해 2025년 5월 19일에 취득한 3,000주를 포함하여 직접적으로 81,000주를 보유하게 되었습니다. 매수는 주당 $1.795에서 $1.82 사이의 가격으로 여러 차례 나누어 이루어졌습니다.

이 고위 임원의 내부자 매수는 회사의 미래 전망에 대한 신뢰를 나타낼 수 있습니다. 해당 거래는 Form 4 신고를 통해 보고되었으며, 증권 규정을 준수하여 2025년 6월 18일 대리인을 통해 신고되었습니다.

Alerte d'Achat d'Initié : Colleen Sjogren, Directrice Commerciale de Nuvation Bio (NUVB), a acquis 50 000 actions de Classe A Common Stock le 16 juin 2025, à un prix moyen pondéré de 1,807 $ par action, représentant un investissement total d'environ 90 350 $.

Suite à cette transaction, Sjogren détient désormais directement 81 000 actions bénéficiaires, incluant 3 000 actions acquises précédemment via le Plan d'Achat d'Actions Employés 2021 de la société, le 19 mai 2025. L'achat a été réalisé en plusieurs transactions avec des prix variant entre 1,795 $ et 1,82 $ par action.

Cette acquisition par un cadre supérieur pourrait indiquer une confiance dans les perspectives futures de l'entreprise. La transaction a été déclarée via le dépôt du Formulaire 4 et exécutée conformément aux régulations sur les valeurs mobilières, le dépôt ayant été effectué par un mandataire le 18 juin 2025.

Insider-Kaufmeldung: Colleen Sjogren, Chief Commercial Officer von Nuvation Bio (NUVB), hat am 16. Juni 2025 50.000 Aktien der Klasse A Common Stock zu einem gewichteten Durchschnittspreis von 1,807 $ pro Aktie erworben, was einer Gesamtinvestition von etwa 90.350 $ entspricht.

Nach dieser Transaktion besitzt Sjogren nun direkt wirtschaftlich 81.000 Aktien, darunter 3.000 Aktien, die zuvor am 19. Mai 2025 über den Mitarbeiteraktienkaufplan 2021 des Unternehmens erworben wurden. Der Kauf erfolgte in mehreren Transaktionen zu Preisen zwischen 1,795 $ und 1,82 $ pro Aktie.

Dieser Insider-Kauf eines leitenden Angestellten könnte auf Vertrauen in die zukünftigen Aussichten des Unternehmens hinweisen. Die Transaktion wurde über eine Form 4-Meldung gemeldet und unter Einhaltung der Wertpapierbestimmungen ausgeführt, wobei die Meldung am 18. Juni 2025 durch einen Bevollmächtigten eingereicht wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sjogren Colleen

(Last) (First) (Middle)
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/16/2025 P 50,000 A $1.807(1) 81,000(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
2. Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
/s/ Stephen Dang, Attorney-in-Fact 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of NUVB did Chief Commercial Officer Colleen Sjogren purchase on June 16, 2025?

Colleen Sjogren purchased 50,000 shares of NUVB Class A Common Stock on June 16, 2025 at a weighted-average price of $1.807 per share.

What is the total number of NUVB shares owned by Colleen Sjogren after her June 2025 purchase?

Following the reported transaction, Colleen Sjogren beneficially owned 81,000 shares of NUVB directly. This total includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan in May 2025.

What was the price range for NUVB shares purchased by Sjogren in the June 2025 transaction?

The shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82 per share, with a weighted-average price of $1.807.

When did NUVB's Chief Commercial Officer last purchase shares through the Employee Stock Purchase Plan?

According to the filing, Colleen Sjogren acquired 3,000 shares through NUVB's 2021 Employee Stock Purchase Plan on May 19, 2025.
Nuvation Bio Inc

NYSE:NUVB

NUVB Rankings

NUVB Latest News

NUVB Latest SEC Filings

NUVB Stock Data

690.73M
274.53M
26.68%
58.95%
7.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO